SCHEMBL4480301

SCHEMBL4480301

CN1CCCN(c2ccccc2CC2CCNC2=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.54
DRD2 P14416 3/20 0.40
DRD3 P35462 3/20 0.40
DRD4 P21917 2/20 0.40
HTR2A P28223 2/20 0.40
HTR1A P08908 1/20 0.40
HTR2C P28335 1/20 0.40
BRD9 Q9H8M2 6/20 0.38
BRPF1 P55201 3/20 0.38
BRD4 O60885 2/20 0.38
BRD7 Q9NPI1 2/20 0.38
KMT2A Q03164 2/20 0.37
EGFR P00533 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
ADRA2C P18825 1/20 0.37
MEN1 O00255 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4732267 0.95 NCF1 (0.46) NCF1DRD2DRD3DRD4HTR2A
SCHEMBL5611262 0.95 NCF1 (0.46) NCF1DRD2DRD3DRD4HTR2A
SCHEMBL1737562 0.95 NCF1 (0.46) NCF1DRD2DRD3DRD4HTR2A
SCHEMBL4477924 0.91 NCF1 (0.47) NCF1DRD2DRD3DRD4HTR2A
SCHEMBL4474160 0.83 CHRNA7 (0.39) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL1740973 0.83 HTR1A (0.47) NCF1DRD2DRD3DRD4HTR2A
SCHEMBL4467894 0.80 PTGER3 (0.41) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL1739004 0.80 ALK (0.47) DRD2DRD3DRD4KDM4EALDH1A1
SCHEMBL4479143 0.80 MAPT (0.39) DRD2DRD3DRD4HTR1ALMNA
SCHEMBL4475156 0.79 PTGER3 (0.33) KMT2ALMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7479559-B2 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation PFIZER INC. (US) 2009-01-20 US disclosed
CN-1934081-A Novel benayl(idene)-lactam derivatives PFIZER (US) 2007-03-21 CN disclosed
US-20050245521-A1 Novel benayl(idene)-lactam derivatives PFIZER INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245521-A1 Novel benayl(idene)-lactam derivatives HTR1E, HTR1D, HTR1A NCF1 4634/4885DRD2 69/4885DRD3 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.